Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study

Albayaty, Muna; Linden, Margareta; Olsson, Håkan; Johnsson, Markus; Strandgården, Kerstin; Tiberg, Fredrik

doi:10.1007/s12325-016-0472-9

Cited by 41 publications

(42 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The slow diffusive release of drugs has been harnessed in the formulation of long acting injectable depot systems for peptide hormones and pain medications to reduce the frequency of injection of these medicines to benefit the patient. In this way they present a viable alternative option to biodegradable polymers often used for such applications, which have disadvantages of the requirement for solvents in development, acidic breakdown products which can degrade the drug, and substantial regulatory hurdles.…”

Section: Technological Applications Of Lipidic Lyotropic Liquid Crystmentioning

confidence: 99%

Nature‐Inspired Design and Application of Lipidic Lyotropic Liquid Crystals

et al. 2019

View full text Add to dashboard Cite

Amphiphilic lipids aggregate in aqueous solution into a variety of structural arrangements. Among the plethora of ordered structures that have been reported, many have also been observed in nature. In addition, due to their unique morphologies, the hydrophilic and hydrophobic domains, very high internal interfacial surface area, and the multitude of possible order−order transitions depending on environmental changes, very promising applications have been developed for these systems in recent years. These include crystallization in inverse bicontinuous cubic phases for membrane protein structure determination, generation of advanced materials, sustained release of bioactive molecules, and control of chemical reactions. The outstanding diverse functionalities of lyotropic liquid crystalline phases found in nature and industry are closely related to the topology, including how their nanoscopic domains are organized. This leads to notable examples of correlation between structure and macroscopic properties, which is itself central to the performance of materials in general. The physical origin of the formation of the known classes of lipidic lyotropic liquid crystalline phases, their structure, and their occurrence in nature are described, and their application in materials science and engineering, biology, medical, and pharmaceutical products, and food science and technology are exemplified. Amphiphilic LipidsThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.

show abstract

Section: Technological Applications Of Lipidic Lyotropic Liquid Crystmentioning

confidence: 99%

Nature‐Inspired Design and Application of Lipidic Lyotropic Liquid Crystals

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The safety and efficacy of buprenorphine implants have been reported (Ling et al, 2010;Rosenthal et al, 2013). Although research into depot buprenorphine injections is still relatively new (Albayaty et al, 2017;Haasen, Linden, & Tiberg, 2017;Haight et al, 2019;Nasser et al, 2016;Walsh et al, 2017), findings indicate promising results regarding its therapeutic effectiveness and tolerability (Lofwall et al, 2018). Indeed, the safety profile of depot buprenorphine appears generally consistent with that of oral buprenorphine, apart from some mild-to-moderate injection-site reactions (Haight et al, 2019;Lofwall et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder

Tompkins

Neale

Strang

2019

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

A B S T R A C TAims: Prolonged-release implantable and depot injection formulations of buprenorphine are very recent developments in the treatment of opioid use disorder. Such formulations remove the need for daily dosing and provide patients with sustained concentrations of buprenorphine over a period of weeks or months. We explored opioid users' personal willingness to receive prolonged-release buprenorphine depot injections and factors influencing their interest. Methods: The study took place in London during 2018, before depot buprenorphine was licensed for use in Europe. Thirty-six face-to-face, semi-structured qualitative interviews were conducted with people who were: i) using heroin daily and not receiving any treatment for opioid use (n = 12); or ii) prescribed daily oral buprenorphine (n = 12); or iii) prescribed daily oral methadone (n = 12). Participants were asked about their willingness to receive depot buprenorphine and were encouraged to discuss factors that might alter their opinions. Interview data were analysed following the stages of Iterative Categorization. Findings: Participants expressed a high level of willingness to receive depot buprenorphine. Their views were influenced both positively and negatively by six key features of depot buprenorphine: i) reduced contact with pharmacies and drug treatment services; ii) impact on illicit drug use and recovery; iii) the perceived effectiveness of depot buprenorphine; iv) the duration and dosage of depot buprenorphine injections; v) clinical administration of the depot buprenorphine injection; and vi) potential for side effects associated with the depot buprenorphine injection. Conclusions: Willingness to receive a given medication is complex, individual and changeable. Opioid users seem likely to welcome greater choice and flexibility in respect of opioid agonist medications and appear more likely to accept and adhere to depot buprenorphine if it enables them to reduce their illicit drug use and facilitates their recovery. Research is now needed to assess whether patients' reported willingness to receive depot buprenorphine translates into actual uptake and adherence. (Clinical Guidelines on Drug Misuse and Dependence (Update), 2017).

show abstract

“…Pharmakologie (Übersicht zu allen Präparaten in [37] Für CAM 2038 sind 2 verschiedene Depotformulierungen verfügbar. Buprenorphin ist in einem Gel enthalten, aus dem sich die Wirksubstanz langsam löst [38]. 4 Dosierungsalternativen für wöchentliche, 3 für monatliche Applikationen stehen zur Verfügung.…”

Section: Subcutan Injizierbares Depotpräparat Cam 2038 (Buvidal ® )unclassified

“…Die Substanz ist pharmakologisch und klinisch wirksam. Walsh et al [38] konnten zeigen, dass 24 und 32 mg Buvidal die Wirkung des intramuskulär gegebenen Opioids Hydromorphon blockierten. Sowohl die wöchentliche wie die monatliche Injektion von CAM 2038 führten zu einer raschen und dauernden Blockade der hydromorphonvermittelten opioidergen Effekte.…”

Section: Subcutan Injizierbares Depotpräparat Cam 2038 (Buvidal ® )unclassified

Langwirksame Buprenorphinpräparate als neue pharmakologische Option bei Opiatabhängigkeit

Soyka¹

2019

Suchttherapie

View full text Add to dashboard Cite

ZusammenfassungDie Opioidsubstitution mit Methadon (oral) oder Buprenorphin (sublingual) ist eine etablierte weltweit praktizierte First-Line-Behandlung der Opiatabhängigkeit. Beide Substanzen müssen täglich oder zumindest alle 2 Tage (Buprenorphin) gegeben werden. Langwirksame Opioide standen zur Substitution nicht zur Verfügung. Das ändert sich jetzt mit dem bereits zugelassenen, wöchentlich oder monatlich subkutan injizierbaren Buprenorphin Depot CAM 2038 (Buvidal®), dem monatlich zu applizierenden Depotpräparat RBP-6000 (Sublocade™) und dem 6-Monate wirkenden Buprenorphin Depot-Implantat (Probuphine™). Klinische Befunde und mögliche Indikationen dieser Medikamente werden diskutiert.

show abstract

Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study

Abstract: Camurus AB.

Cited by 41 publications

References 15 publications

Nature‐Inspired Design and Application of Lipidic Lyotropic Liquid Crystals

Nature‐Inspired Design and Application of Lipidic Lyotropic Liquid Crystals

Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder

Langwirksame Buprenorphinpräparate als neue pharmakologische Option bei Opiatabhängigkeit

Contact Info

Product

Resources

About